Durable remissions in TCF3-HLF positive acute lymphoblastic leukemia with blinatumomab and stem cell transplantation
| العنوان: | Durable remissions in TCF3-HLF positive acute lymphoblastic leukemia with blinatumomab and stem cell transplantation |
|---|---|
| المؤلفون: | Volkan Hazar, Sema Anak, Brice Mouttet, Sarah Elitzur, Jean-Pierre Bourquin, Martin Schrappe, Benoit Brethon, Luciana Vinti, Jerry Stein, Martin Stanulla, Philip Ancliff, Yöntem Yaman, Ajay Vora, Anja Möricke, Joachim B. Kunz, Christiane Chen-Santel, Nicole Bodmer, Gunnar Cario, Franco Locatelli, Arend von Stackelberg, André Baruche |
| المساهمون: | Mouttet, Brice, Bodmer, Nicole, Bourquin, Jean-Pierre Univ Childrens Hosp Zurich, Pediat Oncol, Zurich, Switzerland, Vinti, Luciana, Locatelli, Franco Sapienza Univ Rome, IRCCS Osped Bambino Gesu, Dept Pediat Haematooncol, Rome, Italy, Ancliff, Philip, Vora, Ajay Great Ormond St Hosp Sick Children, Haematol & Oncol Dept, London, England, Brethon, Benoit, Baruchel, Andre Hop Robert Debre, AP HP, Dept Pediat Hematol, Paris, France, Cario, Gunnar, Moericke, Anja, Schrappe, Martin Christian Albrechts Univ Kiel, ALL BFM Study Grp, Dept Pediat 1, Kiel, Germany, Schrappe, Martin Univ Med Ctr Schleswig Holstein, Kiel, Germany, Chen-Santel, Christiane, von Stackelberg, Arend Charite, Dept Pediat Oncol Hematol, Berlin, Germany, Elitzur, Sarah Tel Aviv Univ, Sackler Fac Med, Schneider Childrens Med Ctr, Pediat Hematol Oncol, Tel Aviv, Israel, Hazar, Volkan, Yaman, Yontem, Anak, Sema Medipol Univ Hosp, Dept Pediat Hematol, Istanbul, Turkey, Kunz, Joachim Heidelberg Univ, Pediat Oncol Hematol & Immunol, Heidelberg, Germany, Stein, Jerry Tel Aviv Univ, Sackler Fac Med, Schneider Childrens Med Ctr, Bone Marrow Transplant Unit, Tel Aviv, Israel, Schrappe, Martin Christian Albrechts Univ Kiel, Univ Med Ctr, Pediat, Kiel, Germany, Stanulla, Martin Hannover Med Sch, Pediat Hematol & Oncol, Hannover, Germany, University of Zurich, Bourquin, Jean-Pierre |
| المصدر: | Haematologica. 104:e244-e247 |
| بيانات النشر: | Ferrata Storti Foundation (Haematologica), 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Oncogene Proteins, Fusion, Oncogene Proteins, 2720 Hematology, 610 Medicine & health, EDDY, Antineoplastic Agents, Immunological, Text mining, immune system diseases, hemic and lymphatic diseases, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Antibodies, Bispecific, medicine, Homologous chromosome, Humans, Transplantation, Homologous, Combined Modality Therapy, Online Only Articles, Mandibular Molar, business.industry, Hematopoietic Stem Cell Transplantation, Consolidation Chemotherapy, Hematology, Transplantation, Treatment Outcome, 10036 Medical Clinic, Smear Layer, Cancer research, Blinatumomab, Debris, Stem cell, business, Root Canal Preparation, medicine.drug |
| الوصف: | WOS: 000469839300005 PubMed ID: 30765470 TCF3-HLF-positive leukemia represents a rare subtypeof childhood acute lymphoblastic leukemia (ALL), characterized by a high rate of treatment failure despite treatment intensification and allogeneic stem cell transplantation (SCT). Given the high and homogeneous expressionof CD19 on blast cells of this leukemia subtype, thesepatients may benefit from CD19-directed immunotherapy. Here, we report the experience on nineTCF3-HLF-positive ALL patients, most of whom weretreated early in first consolidation with blinatumomab asa bridge to SCT between 2015 and 2018. Treatment withblinatumomab was generally well tolerated; reversibleneurotoxicity was observed in two patients. All ninepatients achieved molecular remission after blinatumomab treatment; seven underwent SCT and for onepatient SCT is planned. Median follow up after start ofblinatumomab treatment was 342 days, and four patientsremain in molecular remission after a follow up of 1317,1292, 1245, and 342 days, respectively. Three patientsdied because of infectious complications not directlyrelated to blinatumomab, because they occurred eitherafter SCT or after emergence of a CD19-negativeleukemia clone. In the light of these encouraging observations, CD19-directed immunotherapy should be considered early after induction chemotherapy inTCF3-HLF-positive ALL children and patients’ outcomemonitored systematically by study groups. |
| وصف الملف: | haematol.2018.210104.full.pdf - application/pdf; application/pdf |
| تدمد: | 1592-8721 0390-6078 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ae48e41660075ec207a495b52407a34 https://doi.org/10.3324/haematol.2018.210104 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....3ae48e41660075ec207a495b52407a34 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15928721 03906078 |
|---|